Adcetris (brentuximab vedotin) medical benefit coverage
Customize your policy alerts
Sign up for Geisinger Health Plan Policy MBP 166.0 alerts
Get alerted when Policy MBP 166.0 changes without checking for updates manually.
Monitor payer policy activity
Defines medical necessity criteria and prior authorization requirements for Adcetris (brentuximab vedotin) for Geisinger Health Plan members across applicable lines of business. Affects providers prescribing or requesting coverage for Adcetris.
No material clinical or coverage changes in this revision.
Medical Necessity & Coverage Criteria
Medical Necessity Criteria by Indication
Covered when ALL of the following are met:
Grandfather provision: members already on therapy may be approved with documentation of FDA approval or adequate evidence
Classical Hodgkin Lymphoma (cHL) - indication options
- Post-auto-HSCT relapse: Patient at least 18 years of age AND medical record documentation of failure of autologous hematopoietic stem cell transplant (auto-HSCT)
- Failure of ≥2 chemo regimens: Patient at least 18 years of age AND medical record documentation of failure of at least 2 multi-agent chemotherapy regimens and patient is not a candidate for auto-HSCT
- Consolidation post-auto-HSCT: Patient at least 18 years of age AND medical record documentation of use as consolidation treatment following auto-HSCT in high-risk patients (refractory to first line, relapse within 12 months, or extranodal disease)
- Previously untreated advanced cHL (adult): Patient at least 18 years of age AND medical record documentation of previously untreated Stage III or IV cHL AND documentation that Adcetris will be used in combination with doxorubicin, vinblastine, and dacarbazine
- Previously untreated high-risk cHL (pediatric): Patient at least 2 years of age AND medical record documentation of previously untreated high-risk cHL AND documentation that Adcetris will be used in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide
Document prior regimen failure or planned combination use
Peripheral T-cell Lymphomas (PTCL)
Covered when ALL of the following are met for Peripheral T-cell Lymphomas (PTCL):
Relapsed or Refractory LBCL
Covered when ALL of the following are met for Relapsed or Refractory Large B-Cell Lymphoma (LBCL):
This section does not list any explicit exclusions. The policy states that Adcetris (brentuximab vedotin) will be considered medically necessary when all listed criteria are met and includes a grandfather provision for members already established on therapy, but it does not enumerate specific exclusionary conditions in the coverage criteria portion of the document.
Coverage and any line-of-business specific benefit limitations or exclusions are governed by eligibility and contract terms for each line of business. Coverage statements in the applicable line-of-business benefit document supersede this policy, so providers should consult the member's benefit plan for any additional restrictions before requesting authorization.
Within the coverage criteria section itself there are no explicit statements labeling particular uses as “not medically necessary”. The policy defines the conditions under which Adcetris is considered medically necessary but does not provide discrete not-medically-necessary language in this portion of the document.
Coverage for Adcetris will be discontinued if the member experiences unacceptable toxicity or worsening of disease. Authorization durations for relapsed indications are typically limited (for example, initial approvals of up to 6 months), and subsequent approvals require documentation of continued disease improvement or lack of progression; therapy must be stopped when toxicity or disease worsening occurs.
Initial Therapy Requirements
Initial Therapy Requirements
Initial therapy coverage conditions are indication-specific and often require prior therapy failure or specified combination regimens.
Relapsed or Refractory LBCL initial therapy
Prior Authorization & Documentation Requirements
Prior authorization required; grandfathering allowed
Prior authorization is required and must be obtained from the Medical Director or designee before Adcetris will be approved. Members already established on Adcetris may be grandfathered if the medical record documents that safety and effectiveness for the prescribed indication are supported by FDA approval or adequate medical/scientific evidence.
- Grandfather provision: members already established on therapy are eligible for approval with supporting FDA or medical literature documentation.
Prior authorization — required documentation
Submit prior authorization requests that include documentation of the member’s diagnosis, the prescribing provider’s specialty (hematologist/oncologist), patient age, planned combination therapy (when applicable), and prior lines of therapy or transplant/CAR T eligibility status as specified by indication.
- Diagnosis documented in the medical record.
- Prescriber is a hematologist/oncologist.
- Patient age documented (adult indications generally ≥18 years).
- Planned combination regimen (e.g., with CHOP, lenalidomide plus rituximab, or specific pediatric combinations).
- Prior lines of systemic therapy and eligibility for auto‑HSCT or CAR T when required.
Required prior therapy — document prior regimen failure or ineligibility
Coverage is contingent on medical record documentation of prior therapy failure or ineligibility per indication (e.g., failure of autologous HSCT, failure of ≥2 multi‑agent chemotherapy regimens, failure of prior radiation or systemic therapy, or other specified prior regimen failures).
- Document failure of auto‑HSCT when claimed for post‑transplant relapse.
- Document failure of at least two multi‑agent chemotherapy regimens when required.
- Document failure of prior radiation or systemic therapy for pcALCL or CD30‑expressing MF.
- If claiming ineligibility for transplant/CAR T, include documentation supporting ineligibility.
- For sALCL, document failure of ≥1 prior multi‑agent regimen when applicable.
Relapsed/refractory LBCL — prior therapies and ineligibility required
For relapsed or refractory LBCL, prior authorization requires documentation of two or more prior lines of systemic therapy and that the patient is not eligible for autologous HSCT or CAR T‑cell therapy.
- Prescription must be written by a hematologist/oncologist.
- Medical record documentation of ≥2 prior systemic therapy lines for LBCL.
- Documentation that the patient is not eligible for auto‑HSCT or CAR T‑cell therapy.
Required medical record documentation
Medical records submitted with the prior authorization must support the diagnosis, patient age, prior therapies or transplant status, and the specific combination regimens or reasons for transplant/CAR T ineligibility as specified by indication.
- Clear documentation of diagnosis tied to the specific covered indication.
- Patient age documented (most adult indications require ≥18 years).
- Prior therapy history or transplant/CAR T status and reasons for ineligibility.
- Planned or prior combination regimens documented (e.g., lenalidomide + rituximab; CHOP).
Additional documentation specifics (diagnosis, age, prescriber, CD30)
Include indication‑specific supporting details: diagnosis consistent with the listed indication, patient age (≥18 for adult indications; pediatric criteria where specified), prescribing hematologist/oncologist, and CD30 expression documentation where required.
- Confirm CD30 expression documentation for indications that require it (e.g., CD30‑expressing PTCL).
- Document prescriber specialty as hematologist/oncologist.
- Document patient age and that it meets the age requirement for the indication.
Denial risk for lack of prior authorization
Requests submitted without prior authorization from the Medical Director or designee may be denied; prior authorization must be obtained and supported by the required documentation meeting policy criteria.
- Obtain prior authorization prior to initiating therapy unless member is grandfathered with required documentation.
Coverage discontinuation and Medicaid note
Therapy must be discontinued and will no longer be covered if the member experiences unacceptable toxicity or worsening of disease; Medicaid (GHP Family) requests that do not meet PARP criteria will be evaluated case‑by‑case.
- Discontinue Adcetris for unacceptable toxicity or disease progression.
- Medicaid (GHP Family) exceptions evaluated on a case‑by‑case basis.
Continuation, Grandfathering & Authorization Durations
Continuation/Grandfathering
Grandfather provision for members already established on therapy.
Requires documentation
Continuation and authorization duration rules
Authorization durations and requirements for subsequent approvals vary by indication and require documentation of benefit or literature support for extension:
Step Therapy / Prior Treatment Table
| Document / Evidence | What must be in the medical record |
|---|---|
| Diagnosis documentation | |
| Medical record showing the specific diagnosis (e.g., cHL, sALCL, pcALCL, PTCL, LBCL) and patient age as required by the indication (age ≥18 for most adult indications; age ≥2 for previously untreated high‑risk pediatric cHL) |
| Required prior therapies or status | Documentation required to demonstrate failure or ineligibility |
|---|---|
| Relapsed or refractory LBCL: ≥2 prior systemic therapy lines | |
| Medical record documentation listing the two or more prior lines of systemic therapy (regimens and dates) and clinical evidence of progression or nonresponse to those therapies | |
| Ineligibility for auto‑HSCT or CAR T‑cell therapy (LBCL) | |
| Medical record explanation why patient is not eligible for autologous HSCT or CAR T‑cell therapy (e.g., comorbidities, prior transplant failure, organ dysfunction), with treating hematologist/oncologist statement documenting ineligibility | |
| Failure of autologous HSCT (cHL-specific) | |
| Medical record documenting prior auto‑HSCT and subsequent relapse or progression after transplant | |
| Failure of ≥2 multi‑agent chemotherapy regimens (cHL-specific, transplant-ineligible) | |
| Medical record documenting the specific multi‑agent regimens tried and evidence of treatment failure or intolerance, and statement that patient is not a candidate for auto‑HSCT | |
| Failure of prior radiation or systemic therapy (pcALCL / CD30‑expressing MF) | |
| Medical record documenting prior radiation and/or systemic therapy and documentation of failure or intolerance |
Site-of-Care & Benefit Limitations
Site‑of‑care: check line‑of‑business and contract limits for infusion center
Line‑of‑business benefit documents may define site‑of‑care limitations; check eligibility and contract‑specific benefit limitations for infusion center coverage and any site‑of‑care restrictions.
- Verify line‑of‑business benefit document for site‑of‑care limitations.
- Eligibility and contract specific limits may apply to infusion center coverage.
Key Definitions
Background
Adcetris (brentuximab vedotin) is an antibody–drug conjugate composed of a CD30-targeting monoclonal antibody linked to the cytotoxic agent monomethyl auristatin E (MMAE). After binding CD30 on tumor cells, the conjugate is internalized and a protease-cleavable linker releases MMAE intracellularly. MMAE disrupts microtubule dynamics causing G2/M cell-cycle arrest and apoptosis, providing targeted cytotoxicity against CD30-expressing lymphomas.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.